Summarized by Masters of Longevity from PR Newswire.
Phase III trial results show a domestically developed HER2-targeting antibody–drug conjugate improved progression-free survival and response versus an established comparator in advanced HER2-positive breast cancer.
Key Takeaways
- Median progression-free survival was 11.1 months with the new ADC versus 4.4 months with the comparator, hazard ratio 0.39.
- Objective response rate was 76.9% for the new ADC versus 53.0% for the comparator, with longer median duration of response.
- Safety profile showed lower hematologic, hepatic, and gastrointestinal toxicities and fewer serious adverse events with the new ADC.
